Ask A Virologist: How Does GlaxoSmithKline's Potential Coronavirus Vaccine Work?

Pfizer (NYSE: PFE) and its German partner BioNTech (NASDAQ: BNTX) reported incredible efficacy data from a phase 3 trial for their mRNA coronavirus vaccine candidate. This news, paired with the equally impressive data from Moderna (NASDAQ: MRNA) about its candidate that takes a similar approach, inspired much hope around the world and injected optimism into the stock market.

We spoke with Dr. Angela Rasmussen, a virologist and Associate Research Scientist at Columbia Center for Infection and Immunity, about one of the companies working on a COVID-19 vaccine that hasn't been hogging the headlines: GlaxoSmithKline (NYSE: GSK).

 

Continue reading

Source Fool.com